Q UALITY R EPORTING F OR C OLONOSCOPY I N IBD Gil Y. Melmed, MD, MS Cedars-Sinai Medical Center CCFA Advances in IBD Orlando, FL December 2014.

Slides:



Advertisements
Similar presentations
Indeterminate colitis Karel Geboes. Case History Male patient, ° : Hyperthyroidism 1996 : PSC 2003 : Ulcerative colitis –2006 : surveillance.
Advertisements

Crohns Disease: Managing and Monitoring Mucosal Healing in the Small Bowel
Implementing NICE guidance
Miguel Regueiro, M.D. Professor of Medicine
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.
Colitis in the Very Young
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.
How Should We be Assessing and Documenting Endoscopies in IBD: Incorporating Standard Scoring Systems into Patient Care Gary R Lichtenstein, MD Director,
INTRODUCTION  Comparative effectiveness research (CER) is an emerging field that compares the relative effectiveness of alternative strategies to prevent,
©2013 MFMER | Division of GASTROENTEROLOGY & HEPATOLOGY Use and Misuse of CT and MR Imaging in IBD David H. Bruining, MD Mayo Clinic, Rochester,
Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.
Laparoscopic Colon Surgery
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Prevention of Postoperative Crohn’s disease
Practice Guidelines and Consensus on Capsule Endoscopy
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Inflammatory Bowel Disease
Crohn’s disease - A Review of Symptoms and Treatment
Practice Guidelines and Consensus on Capsule Endoscopy
Critical Appraisal of Clinical Practice Guidelines
Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
How to Institute Quality Improvement Initiatives In Your Practice Gil Y. Melmed, MD, MS Cedars-Sinai Medical Center CCFA Advances in IBD Orlando, FL 2014.
Thomas Ullman, M.D. Associate Professor of Medicine
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Colonoscopy; Surveillance Indications
Critical Evaluation of colonoscopic biopsies in Crohn’s Disease Najib Haboubi MB Ch B,D Path, FRCPath Professor of Health Science, Liver and Gastrointestinal.
“Antibiotics and corticosteroids: Indications and approaches”
The association between endoscopic and histological inflammation in ulcerative colitis Klaus Theede, MD Gastrounit, Medical Division Copenhagen University.
Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.
1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
CLINICAL AND ENDOSCOPIC CORRELATION OF INFLAMMATORY BOWEL DISEASE Coordinator: Prof. Univ. Dr. Simona Băţagă Students: Andra Oltean Stoica Ioan Adrian.
(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.
The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1.
Development of CCFA Partners Kids & Teens: an Internet-Based Cohort of Pediatric IBD Michael D. KappelmanWenli Chen Christopher F. MartinBeth Jaeger Erin.
You Can Never Stop a Biologic
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
(A) Surveillance colonoscopies for detecting dysplasia and preventing colorectal carcinoma. (B) Management of visible lesions at endoscopy. A visible lesion.
Quality of Colonoscopy Using an endoscopic database to measure and improve quality AAPCE Memphis- November 5, 2011 David Lieberman MD Chief, Division of.
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis SANDRO ARDIZZONE,* ANDREA CASSINOTTI,*
Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,
MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.
High frequency of early colorectal cancer in inflammatory bowel disease M W M D Lutgens, F P Vleggaar, M E I Schipper, P C F Stokkers, C J van der Woude,
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Clinical process indicators
Dr Gill Watermeyer IBD Clinic Division of Gastroenterology
Value of Fecal Calprotectin and CRP in monitoring IBD
Cumulative Probability of Developing Colon Cancer in UC Patients
Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.
BACKGROUND METHODS RESULTS CONCLUSION DISCUSSION
Repeat Colonoscopy Recommendations
J.Livie1, E.Goodall1, M.Wilson2,C.Payne2 Department of Surgery2
Clinical Correlates of Mental Health Issues in Outpatients with Inflammatory Bowel Disease under Routine Care Taryn Lores Health Psychologist, IBD Service.
Optimizing Use of Biological Agents in Ulcerative Colitis
Feeling Rushed? Does Late Start Time Predict Poor Quality Colonoscopy?
Surveillance of Dysplasia in Inflammatory Bowel Disease: The Gastroenterologist- Pathologist Partnership  David T. Rubin, Jerrold R. Turner  Clinical Gastroenterology.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Raymond Cross, MD, MS, AGAF Associate Professor of Medicine
Volume 145, Issue 5, Pages e5 (November 2013)
Eligibility criteria for inclusion as an expert Delphi panellist
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nursing care of patients operated-on for CRC
Presentation data from US VICTORY Consortium
Crohn’s Disease Biologic Pathway
Slides compiled by Dr. Najma Ahmed
Presentation transcript:

Q UALITY R EPORTING F OR C OLONOSCOPY I N IBD Gil Y. Melmed, MD, MS Cedars-Sinai Medical Center CCFA Advances in IBD Orlando, FL December 2014

Disclosure I disclose the following financial relationships with commercial entities that produce health care–related products or services relevant to the content I am planning, developing, or presenting: Consultant: Amgen, AbbVie, Celgene, Given Imaging, Janssen, Luitpold, Takeda, UCB Research funding: Pfizer, Shire, Prometheus Clinical trial investigator: AbbVie, Amgen, Celgene, Given Imaging, Hutchison Pharma, Janssen, Pfizer, Takeda Gil Y. Melmed, MD, MS

Overview Why are we discussing this? – Variation – Mucosal healing What is a high quality endoscopy report? What can we start doing on Monday to improve the quality of endoscopy reporting?

What is the purpose of an endoscopy procedure report? What was done – Type of procedure, interventions, biopsies Why was it done – Indication for procedure How was it done – Scope, distance, biopsies – Standardized mucosal description – Perianal description IBD needs more! – Pre-procedure Disease phenotype Current medications Last procedure – Intraprocedure: Mucosal inflammation and healing Disease extent – Postprocedure Implications Next steps

Improving the Quality of Endoscopy Reporting in IBD Recommended elements to be included in colonoscopy reports have been proposed by societies, but primarily in the context of colon cancer screening. 1,2 There is little literature and no consensus on what elements constitute a high quality procedure report for patients with IBD 1 Rex et al Gastroint Endos Armstrong Can J Gastro 2012

Quality Reporting for Colonoscopy (not just IBD)

Generic Quality Indicators: Indication for Procedure Indication for Procedure – Is the procedure indication appropriate? Up to 40% of endoscopic procedures may be inappropriate – Justify! Disease monitoring Dysplasia surveillance Exclude infection Assess disease extent Informed consent Rex AJG 2006 Vader GIE 2000

Variation in Colonoscopy Reporting Percentage of reports, with information on a prior colon examination for patients who received polyp surveillance, for each practice site. Lieberman et al Gastro Intest Endos 2009; 69: reports

Endoscopy for IBD Critical for management/decision-making Increased focus on mucosal healing Dysplasia issues often come back to endoscopic appearance  documentation Despite this, the quality of endoscopic reporting for patients with inflammatory bowel disease is variable

Clinical Symptoms vs Mucosal Appearance NO CORRELATION! Modigliani R et al. Gastroenterology. 1990;98: Correlation of CDAI vs CDEIS (N=142) R=0.13; P=NS Crohn’s Disease Activity Index (CDAI) Crohn’s Disease Endoscopic Index of Severity (CDEIS)

Why is Mucosal Healing Important? In clinical trials, mucosal healing is an important treatment endpoint – Increasingly used in clinical trials – Mucosal healing is a more objective endpoint than clinical remission for evaluating inflammatory disease activity In clinical practice, mucosal healing can guide medical therapy – Assess disease activity – Growing evidence that mucosal healing is an important goal as it appears to be associated with improved long-term outcomes Decreased likelihood of a flare Decreased progression to disease complications Decreased need for surgery and hospitalization Decreased risk of dysplasia and colorectal cancer (CRC) 11 de Chambrun GP, et al. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.

Retrospective cohort 102 patients with active CD Severe endoscopic lesions (SEL) defined as deep ulcerations >10% of mucosal area with at least one colonic segment Risk of colectomy associated with SELs, high CDAI, absence of immunosuppression Prognosis of Crohn’s Disease Patients with Severe Ulcerations % Colectomy Years 6% 62% 18% 42% 8% 31% Allez M, et al. Am J Gastroenterol. 2002;97(4):

You’ve just seen this patient for a second opinion….. What does this tell us about the patients prognosis?

Disease Extent Matters (right?) So what does this mean?

SES-CD Range: 0-56

Mayo Endoscopic Subscore Normal Colon (0) Mild Ulcerative Colitis (1) Moderate Ulcerative Colitis (2) Severe Ulcerative Colitis (3) Endoscopic pictures courtesy of Gil Melmed, Cedars-Sinai Medical Center

Rutgeert’s Score Predicts Post-operative Course Higher endoscopic evidence of inflammation (I3 or I4) indicates a higher risk of clinical symptoms and surgery I0I0 No lesions I1I1 < 5 aphthous ulcerations I2I2 > 5 aphthous ulcerations I3I3 Diffuse Aphthous ulcerations I4I4 Large ulcerations, nodules, narrowing Rutgeerts P, et al. Gastro 1990;99:

Reporting Software Defined fields Structured data entry Enhanced communication Safety reporting Quality measures Standardized Patient portals Transcription cost saving Hate… Cumbersome at times Language often incoherent Uses classifications systems with no embedded descriptors Reliance on existing descriptor fields leads to uninformative reports Use of free text (how fast can you type?) prohibits data searching function Time / Learning curve Love…

UMPIRe Project Aim: to utilize an evidence-based consensus approach to develop a QUality TeMPlate for IBD Endoscopy Reporting (UMPIRe) – To incorporate the results of UMPIRe into commercially available endoscopy reporting programs RAND/UCLA appropriateness methodology – A modified Delphi panel iterative approach

Methods RAND Methodology Literature review – 120 proposed elements 1 st Round of online voting of 90 proposed elements 51 elements were included in the final content set Topics: 1. Disease background 2. Findings 3. Dysplasia surveillance 4. Crohn’s disease with anastomosis 5. Pouchoscopy

High Level UMPIRe Results I “Quality Endoscopy Report” Background information – Disease phenotype – Disease duration (especially if surveillance) – Therapy at the time of exam Indication – Describe clinical sx’s (asymptomatic? Flare?) – Dysplasia surveillance? – Disease monitoring?

High Level UMPIRe Results II “Quality Endoscopy Report” Procedure details – Maximum extent of exam (TI intubation? A limb?) – If surveillance – technique used Findings – Descriptors of disease SES-CD Mayo (UC) Rutgeerts score (postop)

One example from “the real world…”

What does this look like in real life?

One example from “the real world…”

What can I do next week? Pick One! – When was surgery? – When last colonoscopy? – What drug(s) is patient on? – How far into ileum? – Rutgeerts score?

Summary Endoscopic appearance of the gut mucosa is one our most important endpoints Endoscopy reporting for IBD is probably highly variable Not all elements are required in every procedure Inclusion of these elements will hopefully improve the quality of reports and improve the quality of care UMPIRe content being added to commercial endoscopy reporting templates